No quarterly revenue total was found in CERO THERAPEUTICS HOLDINGS, INC.'s SEC filings.
Cero Therapeutics Holdings, Inc. (CERO) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $862,756 in cash and investments and $233,101 in total debt.
Revenue
—
Net income
$-1.03M
+81.0% vs year-ago quarter
Operating cash flow
$-7.89M
-381.7% vs prior quarter
Free cash flow
—
EPS
$-0.70
+98.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
71.63M
+5842.5% vs year-ago quarter
Net cash
$629,655
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CERO (OTC), CEROW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1870404
- Former names
- CERO THERAPEUTICS HOLDINGS, INC. (until Oct 7, 2026); PHOENIX BIOTECH ACQUISITION CORP. (until Feb 14, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$3.8M | -$4.8M | — | -$4.4M | -$4.7M |
| Net income | -$1.0M | -$5.9M | -$4.5M | -$4.9M | -$5.4M |
| Diluted EPS | -$0.70 | -$0.20 | — | -$9.10 | -$61.71 |
| Operating cash flow | -$7.9M | $2.8M | — | — | — |
| Total assets | $1.9M | $2.2M | $3.6M | $3.9M | $6.2M |
| Total liabilities | $32.4M | $11.5M | $9.1M | $8.5M | $7.8M |
| Stockholders' equity | -$30.5M | -$9.3M | -$5.4M | -$4.5M | -$1.6M |
| Cash and investments | $862,756 | — | — | $1.9M | $3.2M |
| Total debt | $233,101 | $793,674 | $1.0M | $931,023 | $1.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Oct 7, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt, Unregistered share sale
|
Aug 31, 2026 | Aug 27, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jul 17, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jun 26, 2026 | Jun 23, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
May 29, 2026 | May 28, 2026 |
All 445 Cero Therapeutics Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.